KIT and neoplasm: Three tumors had amplification of both PDGFRA and KIT, and three tumors had amplification of EGFR. We validated copy number estimates for a subset of calls using a variety of different methods, including Taqman quantitative PCR (qPCR; across all tumors for EGFR and tumors BI05, BI06 and BI15 for PDGFRA), as well as whole genome sequencing (in tumor BI15 for EGFR).